Sterling Pharma Solutions Invests into US Expansion

November 1, 2019
Pharmaceutical Technology Editors

Contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has revealed its investment of $1.5 million into a phased expansion of its facility based in North Carolina, United States.

Contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has revealed its investment of $1.5 million into a phased expansion of its facility based in North Carolina, United States.

As reported in an Oct. 28, 2019 press release, the company’s latest investment follows from its acquisition of US CiVentiChem earlier in the year and forms part of the company’s ongoing growth strategy. The investment will be used to expand the cGMP production suites, add non-GMP scale-up production facility, expand the quality control laboratory, and increase the site’s R&D capacity.

“The North American market now makes up 70% of our customer portfolio.And, having expanded our US presence earlier this year with the acquisition of our facility in North Carolina, we have continued to experience strong growth,” said Mat Minardi, president US Operations in the press release. “This investment will allow us to continue to meet customer expectations and take on new projects, as well as bolster Sterling’s chemistry development capabilities. The specialist capabilities provided by Sterling, particularly our ability to handle challenging chemistries, are in high demand as a result of the increasing complexity of products entering the drug pipeline and the need for more efficient and cost-effective production of APIs. We’re confident this investment will be of huge benefit to our customers.”

Sterling Pharma Solutions will be exhibiting at CPhI WW in Frankfurt from Nov. 5–7, 2019 in Hall 10.1, Stand 101A60

Source: Sterling Pharma Solutions